- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02158624
Ranibizumab Treatment for Age-Related Macular Degeneretion (QUATRO)
June 5, 2014 updated by: Yuji Oshima, Kyushu University
The Correlation for Improvement of Visual Acuity and QOL After Ranibizmab Treatment for Age-Related Macular Degeneration Patients
To establish the correlation between visual acuity improvement and QOL measurement after ranibizumab treatment for AMD patients.
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tatsuro Ishibashi, MD. PhD
- Phone Number: +81-92-642-5648
- Email: ishi@eye.med.kyushu-u.ac.jp
Study Contact Backup
- Name: Yuji Oshima, MD. PhD
- Phone Number: +81-92-642-5648
- Email: yuji@eye.med.kyushu-u.ac.jp
Study Locations
-
-
Fukuoka
-
Maidashi, Higashiku, Fukuoka-city, Fukuoka, Japan, 812-8582
- Recruiting
- Department of Ophthalmology, Kyushu University Hospital
-
Contact:
- Yuji Oshima, MD. PhD
- Phone Number: +81-92-642-5648
- Email: yuji@eye.med.kyushu-u.ac.jp
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Active primary or recurrent subfoveal choroidal neovascularization lesion due to AMD
- Subjects of either gender age 50 years or older
- Visual acuity better than 0.05 decimal( 20/400 Snellen)
- Signed informed consent form
Exclusion Criteria:
- Prior treatment for neovascular AMD in the study eye, for example, PDT or anti-VEGF therapy
- Patients whose lesion site evaluated by FA examination is more than 12DA in subject eye
- Patients with treatment of triamcinolone intravitreal injection within 6 months in subject eye
- Patients with a history of intraocular surgical operation(including cataract)within 3 months in subject eye
- Patients with serious allergic history to such as fluorescein, indocyanine green, iodophors
- The pregnant or lactating woman
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ranibizumab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Baseline change of visual acuity and QOL after ranibizumab treatment
Time Frame: 3 months
|
Analyze the correlation between visual acuity improvement and QOL assessment using VFQ-25 and Patient Satisfaction Questionnaire before and after initial ranibizumab treatment for AMD patients.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the correlation between the changes of visual acuity and QOL measurement during one year follow-up observations
Time Frame: 1year
|
1year
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Baseline change of central retinal thickness by OCT examination.
Time Frame: 3 months, 1 year
|
3 months, 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2013
Primary Completion (Anticipated)
April 1, 2015
Study Completion (Anticipated)
December 1, 2015
Study Registration Dates
First Submitted
June 5, 2014
First Submitted That Met QC Criteria
June 5, 2014
First Posted (Estimate)
June 9, 2014
Study Record Updates
Last Update Posted (Estimate)
June 9, 2014
Last Update Submitted That Met QC Criteria
June 5, 2014
Last Verified
June 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13-E-09
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Visual Disorder Due to Age-related Macula Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNVGermany
-
BayerRecruitingVisual Impairment | Neovascular Age-related Macular Degeneration (nAMD) | Diabetic Macula Edema (DME)Germany, United Kingdom, Canada, Denmark, France, Italy, Saudi Arabia, Switzerland, Australia, Finland, Netherlands, Sweden, Norway, United Arab Emirates, Japan
-
Brighton and Sussex University Hospitals NHS TrustCompletedAge Related Macular Degeneration | Cataract Senile | Epiretinal Membrane | Vitreomacular Traction | Macula HoleUnited Kingdom
-
Novartis PharmaceuticalsWithdrawnVisual Impairment Due to Diabetic Macular EdemaGermany
-
Notal Vision Inc.CompletedNeovascular Age-related Macular Degeneration | Intermediate Age Related Macular Degeneration (Disorder)United States
-
Novartis PharmaceuticalsWithdrawnVisual Impairment Due to Diabetic Macular Edema
-
Novartis PharmaceuticalsTerminatedVisual Impairment Due to Diabetic Macular EdemaGermany
-
Novartis PharmaceuticalsActive, not recruitingDiabetic Macular Edema (DME) | Neovascular Age-related Macular Degeneration (nAMD)Germany
-
Nu Eyne Co., Ltd.RecruitingEarly to Moderate Dry Age-Related Macular DegenerationKorea, Republic of
-
Institute of Molecular and Clinical Ophthalmology...Boehringer IngelheimActive, not recruitingAge-Related Macular Degeneration | Geographic Atrophy | Visual Field Defect, Central Scotoma of Both EyesSwitzerland
Clinical Trials on Intravitreal Lucentis 0.5mg
-
David M. Brown, M.D.Novartis PharmaceuticalsTerminatedAge-Related Macular DegenerationUnited States
-
Dongyang People's HospitalRecruiting
-
RemeGen Co., Ltd.CompletedWet Age-Related Macular DegenerationChina
-
Wonkwang University HospitalNovartis Korea Ltd.CompletedNonproliferative Diabetic Retinopathy
-
Vista KlinikCompletedAge Related Macular Degeneration | Choroidal NeovascularizationSwitzerland
-
Novartis PharmaceuticalsCompletedAge-related Macular Degeneration | Choroidal NeovascularizationKorea, Republic of, Croatia, Germany, India, Russian Federation, Turkey, United Kingdom, Egypt, Israel, Belgium, Denmark, Hungary, Slovenia, Spain, Switzerland, Italy, Portugal, Slovakia, Chile
-
Leonard Feiner, MD, PhDNJ Retina (Retina Associates of New Jersey)CompletedAge-related Macular DegenerationUnited States
-
Chong Kun Dang PharmaceuticalRecruitingEfficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 DiabetesType2 DiabetesKorea, Republic of
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityCompletedChoroidal NeovascularizationChina
-
Southern California Desert Retina Consultants, MCCompletedAge-related Macular DegenerationUnited States